C1071003 - MAGNETISMM-3, An Open-Label, Multicenter, Non-Randomized Phase 2 Study of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One Proteasome Inhibitor, One Immunomodulatory Drug and One Anti-CD38 Antibody
Multiple myeloma is a type of blood cancer that affects plasma cells in your bone marrow. Over time, standard treatments can stop working, which means doctors need new ways to help keep the cancer under control. This Phase 2 study is testing a targeted medicine called elranatamab. Elranatamab is designed to help your body's own immune system locate and attack myeloma cells. Researchers want to see how well the medicine shrinks the cancer and how safe it is for patients whose disease has returned after receiving at least three previous types of standard myeloma treatments. Everyone who joins this study receives elranatamab; there is no dummy treatment (placebo). Doctors will closely track how the cancer responds and monitor any side effects throughout the trial.
At a glance
What is this study about?
Multiple myeloma is a cancer that begins in plasma cells, a kind of white blood cell found in the bone marrow. While there are several effective treatments available today, myeloma can often come back or become resistant to medicines over time. When standard therapies stop working, finding new ways to fight the cancer is essential.
This clinical study, known as MAGNETISMM-3, looks at a medicine called elranatamab. It is a type of targeted treatment known as a bispecific antibody. You can think of it as a bridge: it attaches to the cancer cell on one side and to your body's immune cells (T-cells) on the other. By bringing them together, it helps your immune system recognise and destroy the myeloma cells.
The main goal of this trial is to see how many patients have their cancer shrink or disappear after receiving elranatamab on its own. Researchers also want to find out how long these benefits last, how the drug affects overall survival, and what side effects may occur. Because this is an open-label study, every participant receives the study medicine.
Key takeaways
- Phase 2 clinical trial testing elranatamab for advanced multiple myeloma.
- Aimed at adults whose cancer has not responded to three standard types of treatment.
- Elranatamab works by guiding your immune cells to attack cancer cells.
- All participants receive the study medicine; there is no placebo.
- Participation is entirely voluntary and you can stop at any time.
Who may be eligible?
This trial is open to adults aged 18 and older who have been diagnosed with multiple myeloma. To be eligible, your cancer must be active and not responding well to current treatments.
Importantly, participants must have already received at least three specific groups of myeloma medicines: a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody. Your doctor will check if your previous treatments match these requirements.
Before taking part, your medical team will also check your general health, including blood tests and organ function, to make sure it is safe for you to receive the study drug. People who are pregnant or have certain other severe medical conditions may not be able to take part.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I have been diagnosed with multiple myeloma.
- My cancer has returned or stopped responding to previous treatments.
- I have already tried three specific types of myeloma medicines (proteasome inhibitor, immunomodulatory drug, and anti-CD38 antibody).
- I am able and willing to attend regular hospital appointments for treatment and tests.
What does participation involve?
Taking part involves receiving elranatamab as regular injections, usually given under the skin. At the start of the study, you may receive smaller 'step-up' doses to help your body adjust to the medicine, which may require a short stay in hospital for close observation. After this initial phase, doses are given on a regular schedule as an outpatient.
You will need to attend the clinic regularly for health checks. These visits will include blood and urine tests, physical examinations, heart scans, and occasional bone marrow samples to track how your cancer is responding. Treatment continues for as long as it is helping you and the side effects remain manageable. After finishing treatment, the study team will keep in touch periodically to check on your health.
Potential risks and benefits
Locations (5)
- —UnverifiedBelgium
- —UnverifiedPoland
- —UnverifiedFrance
- —UnverifiedGermany
- —UnverifiedSpain
Common questions
Will I receive a placebo (dummy drug)?
No. In this study, every participant receives the active medicine, elranatamab.
How is the medicine given?
Elranatamab is given as an injection under the skin, usually in your tummy or thigh.
Will I have to stay in hospital?
You may need to stay in hospital for a few days during the very first doses so the medical team can watch closely for any immediate immune reactions.
Can I leave the study if I change my mind?
Yes. You can leave the trial at any point, and your usual healthcare team will support you with other available treatments.
Does it cost anything to take part?
No. The study drug and trial-related tests are provided free of charge, and help with travel expenses is often available.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.